Effect of Probiotic Use Containing Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis on Clinical Outcomes in Children Aged 2–12 Years Receiving Antibiotic Therapy: A Multicenter Cohort Study
Pediatric Practice and Research · 02.08.2026 · 14 (1) · 1989524
DOI: 10.21765/pprjournal.1989524 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pediatric Practice and Research, online erschienen am 02.08.2026. Verfasst von Vefik Arıca und 23 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Gefördert von: None.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objective
This study aimed to evaluate the association between probiotic supplementation containing Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis and antibiotic-associated diarrhea, gastrointestinal tolerability, healthcare utilization, and social outcomes in children aged 2–12 years receiving antibiotic therapy, using real-world clinical data.Materials and Methods: This multicenter cohort study included children aged 2–12 years who were prescribed antibiotic therapy for an infectious diagnosis in pediatric outpatient clinics and/or departments of pediatrics across 15 centers between January 1, 2026, and June 1, 2026. Patients were categorized according to probiotic use during antibiotic therapy into the probiotic group, receiving supplementation containing L. rhamnosus GG and B. animalis subsp. lactis in addition to antibiotics (Group 1, n=120), and the control group, receiving antibiotics alone (Group 2, n=120). The primary outcome was antibiotic-associated diarrhea, defined as three or more loose or watery stools within 24 hours without an alternative clinical explanation. Secondary outcomes included gastrointestinal symptoms, repeat healthcare visits, antibiotic modification or discontinuation, school/daycare absenteeism, and parental workday loss. Continuous variables were compared using the Mann–Whitney U test, whereas categorical variables were analyzed using the chi-square test or Fisher’s exact test, as appropriate. Multivariable logistic regression analysis was performed to identify independent factors associated with antibiotic-associated diarrhea.
Results
A total of 240 children were included, with 120 patients in each group. Baseline characteristics, including age, sex, antibiotic indication, antibiotic class, and duration of antibiotic therapy, were comparable between the groups. The incidence of antibiotic-associated diarrhea was significantly lower in the probiotic group than in the control group (16.7% vs. 32.5%; p=0.007). Probiotic supplementation was associated with a 49% relative reduction in the risk of antibiotic-associated diarrhea (RR=0.51; 95% CI: 0.32–0.83). The probiotic group also had significantly shorter diarrhea duration, lower maximum daily stool frequency, and lower rates of abdominal pain, flatulence, bloating, nausea/vomiting, repeat healthcare visits, hospitalization, antibiotic modification/discontinuation, need for additional treatment, school/daycare absenteeism, and parental workday loss.
Conclusion
In children aged 2–12 years receiving antibiotic therapy, supplementation with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis was associated with a lower incidence of antibiotic-associated diarrhea and a reduced clinical and social burden, supporting its potential role as a practical adjunctive strategy to improve gastrointestinal tolerability during antibiotic treatment.
Förderung
- None
Zitieren
APA
Arıca, V., Sipahier, N., Ozkan, H. Y., Yıldız, E. G. Ö., Kemalbay, H. D., Özgür, F. A., Ademoğlu, A., Dönmez, Ç., Çiftçi, E., Akgün, A. R., Yaşar, Ş. G., Kunt, G. C. B., Dağdeviren, F. E., Kaya, B. B., Hakgör, N. K., Yürük, S., Ulutaş, E., Karaaslan, F., Duman, V., …, & Köle, M. T. (2026). Effect of Probiotic Use Containing Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis on Clinical Outcomes in Children Aged 2–12 Years Receiving Antibiotic Therapy: A Multicenter Cohort Study. Pediatric Practice and Research, 14(1), 1989524. https://doi.org/10.21765/pprjournal.1989524
Vancouver
Arıca V, Sipahier N, Ozkan HY, Yıldız EGÖ, Kemalbay HD, Özgür FA, et al. Effect of Probiotic Use Containing Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis on Clinical Outcomes in Children Aged 2–12 Years Receiving Antibiotic Therapy: A Multicenter Cohort Study. Pediatric Practice and Research. 2026;14(1):1989524. doi:10.21765/pprjournal.1989524
BibTeX
@article{Arca2026,
author = {Arıca, Vefik and Sipahier, Neslihan and Ozkan, Hatice Yildiz and Yıldız, Emine Gözde Özdrama and Kemalbay, Hatice Demet and Özgür, Feyza Aydın and Ademoğlu, Ayşe and Dönmez, Çağla and Çiftçi, Eda and Akgün, Ali Rıza and Yaşar, Şeyma Güler and Kunt, Gülçe Ceren Barlas and Dağdeviren, Fatma Ece and Kaya, Buse Berfin and Hakgör, Nihal Kazar and Yürük, Sümeyye and Ulutaş, Elber and Karaaslan, Fatih and Duman, Vildan and Aygün, Mina Dilara and Kanat, İdil and İnci, Ayşenur and Yurtsever, Ulaş and Köle, Mehmet Tolga},
title = {Effect of Probiotic Use Containing Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis on Clinical Outcomes in Children Aged 2–12 Years Receiving Antibiotic Therapy: A Multicenter Cohort Study},
journal = {Pediatric Practice and Research},
year = {2026},
volume = {14},
number = {1},
pages = {1989524},
doi = {10.21765/pprjournal.1989524}
}
EUVIMED